Emerging global epidemic of obesity: The renal perspective

Annals of Saudi Medicine

Volumn 26, Issue 4, 2006, Pages 288-295

  Saxena, Anil Kumar ^a,b  

^a KING FAHAD HOSPITAL   (Saudi Arabia)

^b SHEIKH KHALIFA MEDICAL CITY   (United Arab Emirates)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTILIPEMIC AGENT; CYTOKINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GLITAZONE DERIVATIVE; HORMONE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ADIPOCYTE; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; CYTOKINE RELEASE; DIABETIC NEPHROPATHY; DIET THERAPY; DISEASE ASSOCIATION; EPIDEMIC; EVIDENCE BASED MEDICINE; FOCAL GLOMERULOSCLEROSIS; HORMONE RELEASE; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; IMMUNOGLOBULIN A NEPHROPATHY; KIDNEY BLOOD FLOW; KIDNEY CARCINOMA; KIDNEY DISEASE; KIDNEY INJURY; KIDNEY TUBULE PRESSURE; LIFESTYLE; METABOLIC SYNDROME X; MICROALBUMINURIA; MORBIDITY; MORTALITY; NEPHROLITHIASIS; NEPHROSCLEROSIS; NEPHROTIC SYNDROME; NONHUMAN; OBESITY; PATHOGENESIS; PRIORITY JOURNAL; PROSTATE CARCINOMA; PROTEINURIA; REVIEW; RISK FACTOR; SOLITARY KIDNEY; UNINEPHRECTOMY; WEIGHT REDUCTION; WORLD HEALTH ORGANIZATION;

EID: 33750592117     PISSN: 02564947     EISSN: 13199226     Source Type: Journal    
DOI: 10.5144/0256-4947.2006.288     Document Type: Review

References (57)

1. World Health Organization. Obesity: preventing and managing the global epidemic. Geneva: WHO, 1998.
2. Flegal KM, Carroll MD, Ogden CL, et al. Prevalence and trends in obesity among US adults, 1999-2000. JAMA 2002; 288:1723-1727.
3. James PT, Leach R, Kalamara E, Shayeghi M. The worldwide obesity epidemic. Obes Res 2001; 9:228-233
4. Sorof J, Daniels S. Obesity hypertension in children-A problem of epidemic proportions. Hypertension 2002; 40:441-47.
5. US Department of Health and Human Services Centers for Disease Control and Prevention Office of Communications. Obesity epidemic increases dramatically in the United States: CDC director calls for national prevention effort 1999. 28 October. Available at: http://www.cdc.gov/od/ oc/media/pressrel/r991026.htm. Accessed December 2, 2003
6. Praga M. Obesity - a neglected culprit of renal disease. Nephrol Dial Transplant 2002; 17: 1157-1159.
7. Hall JE, Henegar JR, Dwyer TM, Liu J, Da Silva AA, Kuo JJ, Tallam L. Is obesity a major cause of chronic kidney disease Adv Ren Replace Ther 2004; 11:41-54
8. Hall JE. The kidney, hypertension, and obesity. Hypertension 2003; 41:625-633
9. Jones DW, Kim JS, Andrew ME, et al. Body mass index and blood pressures in Korean men and women: The Korean National Blood Pressure Survey. J Hypertension 1994; 12:1433-1437.
10. He Q, Ding YZ, Fong DY, et al. Blood pressure is associated with body mass index in both normal and obese children. Hypertension 2000; 36:165-170.
11. Garrison RJ, Kannel WB, Stokes J, et al. Incidence and precursors of hypertension in young adults: The Framingham Offspring Study. Prev Med 1997; 16:235-251.
12. Hall JE. Pathophysiology of obesity hypertension. Curr Hypertens Rep. 2000; 2:139-147
13. Ribstein J, du Cailar G, Mimran A. Combined renal effects of overweight and hypertension. Hypertension 1995;26:610-615
14. Hall JE, Hildebrandt DA, Kuo J. Obesity hypertension: role of leptin and sympathetic nervous system. Am J Hypertens. 2001; 14:103S-115S.
15. Stenvinkel P. Leptin and blood pressure-is there a link? Nephrol Dial transplant. 2000; 15:1115-1117.
16. Martinez-Anso E, Lostao MP, Martinez JA. Immunohistochemical localization of leptin in rat kidney. Kidney Int 1999; 55:1129-1130.
17. Jackson EK, Herzer WA. Human leptin has natriuretic activity in the rat. Am J Physiol. 1997; 272: F333-F338.
18. Sugerman HJ. Effects of increased intra-abdominal pressure in severe obesity. Sung Clin North Am 2001; 81:1063-1075.
19. Hall JE, Crook ED, Jones DW, et al. Mechanisms of obesity-associated cardiovascular and renal disease. Am J Med Sci 2002; 324:127-137
20. Mather KJ, Mirza Mohammedi B, Lteif A, Steinberg HO, Baron AD. Endothelin contributes to basal vascular tone and endothelial dysfunction in human obesity and type-II diabetes. Diabetes 2002; 51:3517-3523
21. Praga M, Hernandez E, Andres A, et al. Effects of body-weight loss and captopril treatment on proteinuria associated with obesity. Nephron 1995; 70:35-41.
22. Miller ER, Erlinger TP, Young DR, et al. Results of the Diet, Exercise, and Weight Loss Intervention Trial (DEW-IT). Hypertension 2002; 40:612-618.
23. He J, Whelton PK, Appel LJ, et al. Long-term effects of weight loss and dietary sodium reduction on incidence of hypertension. Hypertension 2001; 35:544-549.
24. Taddei S, Virdis A, Ghiadoni L, Magagna A, Salvetti A. Vitamin C improves endothelial dependent vasodilatation by restoring nitric oxide activity in essential hypertension. Circulation. 1998; 97:2222-29.
25. Wardle EN. Antioxidants in the prevention of renal disease. Ren Fail 1999; 21:581-591
26. Wesson DE, Kurtzman NA, Prommer JP. Massive obesity and nephrotic proteinuria with a normal renal biopsy. Nephron 1985; 40:235-237.
27. De Jong PE, Verhave JC, Pinto-Sietsma SJ, Hillege HL, For the PREVEND Study group. Obesity and target organ damage: the kidney. Int J Obes Relat Metab Disord 2002; 26:21-24.
28. Liese AD, Hense HW, Doring A, Stieber J, Keil U. Microalbuminuria, central adiposity and hypertension in the non-diabetic urban population of the MONICA Augsburg survey 1994/95. J Hum Hypertens 2001; 15:799-804.
29. Sesatomi Y, Tada M, Uesugi N, Hisano S, Takebayashi S. Obesity associated with hypertension or hyperlipidemia accelerates renal damage. Pathobiology 2901; 69:113-118.
30. Kambham N, Markowitz GS, Valeri AM, Lin J, D'Agati VD. Obesity-related glomerulopathy: an emerging epidemic. Kidney Int 2001; 59(4):1498-1509.
31. Praga M, Hernandez E, Morales E et al. Clinical features and long-term outcome of obesity-associated focal segmental glomerulosclerosis. Nephrol Dial Transplant 2001; 9:1790-1798.
32. Cohen AH. Pathology of renal complications in obesity. Curr Hypertens Rep 1999; 1(2):137-139
33. Verani RR. Obesity-associated focal segmental glomerulosclerosis: pathological features of the lesion and relationship with cardiomegaly and hyperlipidemia. Am J Kidney Dis 1992; 20:629-634.
34. Kasiske BL, O'Donnell MP, Cleary MP, Keane WF. Treatment of hyperlipidemia reduces glomerular injury in obese Zucker rats. Kidney Int 1988; 33:657-672.
35. Morales E, Valero MA, Leon M, et al. Beneficial effects of weight loss in overweight patients with chronic proteinuric nephropathies. Am J Kidney Dis 2003; 41:319-327.
36. Boeing H, Schlehofer B, Wahrendorf J. Diet, obesity and risk for renal cell carcinoma: results from a case control-study in Germany. Z Ernahrungswiss 1997; 36:3-11
37. Moyad MA. Review of potential risk factors for kidney (renal cell) cancer. Semin Urol Oncol 2001; 19:280-293.
38. Gago-Dominguez M, Castelao JE, Yuan JM, Ross RK, Yu MC. Lipid peroxidation: a novel and unifying concept of the etiology of renal cell carcinoma (United States). Cancer Causes Control 2002; 13:287-293.
39. Moyad MA. Obesity, interrelated mechanisms, and exposures and kidney cancer Semin Urol Oncol 2001; 19:270-279.
40. Taylor EN, Stampfer MJ, Curhan GC. Obesity, weight gain, and the risk of kidney stones JAMA 2005;293:455-462.
41. Amling CL. The association between obesity and the progression of prostate and renal cell carcinoma Urol Oncol 2004; 22:478-484.
42. Bonnet F, Deprele C, Sassolas A et al. Excessive body weight as a new independent risk factor for clinical and pathological progression in primary IgA nephritis. Am J Kidney Dis 2001; 37:720-777.
43. Kuiper JJ. Effects of weight reduction and angiotensin-converting enzyme inhibition on IgA nephropathy-associated proteinuria Nephron 1996. 74:462-463.
44. Praga M, Hernandez E, Herrero JC et al. Influence of obesity on the appearance of proteinuria and renal insufficiency after unilateral nephrectomy. Kidney Int. 2000; 58:2111-2118.
45. Wiecek A, Kokot F, Chudek J, Adamczac M. The adipose tissue- a novel endocrine organ of interest to nephrologist. Nephrol dial Transplant 2002; 17:191-195.
46. Adelman RD. Obesity and renal disease. Current Opin Nephrol Hypertens. 2002; 11:331-335.
47. Kiess W, Bottner A, Bluher S, Raile K, Galler A, Kapellen TM. Type 2 diabetes mellitus in children and adolescents-the beginning of a renal catastrophe? Nephrol Dial Transplant 2004;19:2693-2696.
48. Kincaid - Smith P. Hypothesis: obesity and insulin resistance syndrome plays a major role in end stage renal failure attributed to hypertension and labeled hypertensive nephrosclerosis. J Hypertens 2004; 22:1051-1055.
49. Locatelli F, Moccelli D, Cornelli M and North Itallan Cooperative Study Group. Proteinuria and blood pressure as causal components of progression to end stage renal disease. Nephrol Dial Transplant 1996; 11:1-7.
50. Saiki A, Nagayama D, Ohhira M, Endoh K, Ohtsuka M, Koide N, Oyama T, Miyashita Y, Shirai K. Effect of weight loss using formula diet on renal function in obese patients with diabetic nephropathy. Int J Obes Relat Metab Disord. 2005; doi:10.1038/sj.ijo.0803009.
51. Price DA, Lansang MC, Osei SY, Fisher ND, Laffel LM, Hollenberg NK. Type 2 diabetes, obesity, and the renal response to blocking the renin system with irbesarten. Diabet Med. 2002; 19:858-861
52. Brenner BM. Nephron adaptation to renal injury or ablation. Am J Physiol. 1985; 249:F325-F337.
53. Remuzzi G, Ruggenenti P, Benigni A. Understanding nature of renal disease progression. N Eng J Med. 1997; 51:2-15.
54. Klahr S, Morrissey J. Progression of chronic renal disease. Am J Kidney Dis. 2003; 41 (3 Suppl 1):S3-S7.
55. Chagnac A, Weinstein T, Korzets A, et al. Glomerular hemodynamics in severe obesity. Am J Physiol Renal Physiol 2000; 278:F817-F822.
56. Hall JE, Kuo JJ, Silva A, et al. Obesity, hypertension, and renal disease. Curr Opin Nephrol Hypertens 2003; 12:195-200.
57. Saxena AK, Chopra R. Renal risks of emerging "epidemic" of obesity: the role of adipocyte derived factors. Dial Transplant 2004; 33:11-20